Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (apre una nuova finestra)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Fonte‎: Cancer 2013;119(21):3784-7.

Indicizzato‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (apre una nuova finestra)

Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. (apre una nuova finestra)

Avvisati G, ten Cate JW, Büller HR, Mandelli F.

Fonte‎: Lancet 1989;334(8655):122-4.

Indicizzato‎: PubMed 2567893

https://www.ncbi.nlm.nih.gov/pubmed/2567893 (apre una nuova finestra)

Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusions. (apre una nuova finestra)

Ben-Bassat I, Douer D, Ramot B.

Fonte‎: Eur J Haematol 1990;45(2):86-9.

Indicizzato‎: PubMed 2209824

https://www.ncbi.nlm.nih.gov/pubmed/2209824 (apre una nuova finestra)

Fibrinolytic inhibitors for cancer-associated bleeding problems. (apre una nuova finestra)

Dean A, Tuffin P.

Fonte‎: J Pain Symptom Manage 1997;13(1):20-4.

Indicizzato‎: PubMed 9029858

https://www.ncbi.nlm.nih.gov/pubmed/9029858 (apre una nuova finestra)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (apre una nuova finestra)

Ford PA, Grant SJ, Mick R, Keck G.

Fonte‎: J Clin Oncol 2015;33(15):1674-9.

Indicizzato‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (apre una nuova finestra)

Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients. (apre una nuova finestra)

Garewal HS, Durie BG.

Fonte‎: Scand J Haematol 1985;35(5):497-500.

Indicizzato‎: PubMed 4089529

https://www.ncbi.nlm.nih.gov/pubmed/4089529 (apre una nuova finestra)

Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. (apre una nuova finestra)

Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M.

Fonte‎: Cancer 2006;107(1):136-40.

Indicizzato‎: PubMed 16708357

DOI‎: 10.1002/cncr.21958

https://www.ncbi.nlm.nih.gov/pubmed/16708357 (apre una nuova finestra)

Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series. (apre una nuova finestra)

Marshall A, Li A, Drucker A, Dzik W.

Fonte‎: Hematol Oncol 2016;34(3):147-53.

Indicizzato‎: PubMed 25641349

DOI‎: 10.1002/hon.2189

https://www.ncbi.nlm.nih.gov/pubmed/25641349 (apre una nuova finestra)

Tranexamic acid to treat life-threatening hemorrhage in prostate cancer associated disseminated intravascular coagulation with excessive fibrinolysis. (apre una nuova finestra)

Prokopchuk-Gauk O, Brose K.

Fonte‎: Cureus 2015;7(12):e428.

Indicizzato‎: PubMed 26848417

DOI‎: 10.7759/cureus.428

https://www.ncbi.nlm.nih.gov/pubmed/26848417 (apre una nuova finestra)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (apre una nuova finestra)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Fonte‎: Leuk Lymphoma 1995;19(1-2):141-4.

Indicizzato‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (apre una nuova finestra)

Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. (apre una nuova finestra)

Wassenaar T, Black J, Kahl B, Schwartz B, Longo W, Mosher D, Williams E.

Fonte‎: Hematol Oncol 2008;26(4):241-6.

Indicizzato‎: PubMed 18613223

DOI‎: 10.1002/hon.867

https://www.ncbi.nlm.nih.gov/pubmed/18613223 (apre una nuova finestra)

Use of Novoseven for arsenic trioxide-induced bleeding in PML. (apre una nuova finestra)

Alimoghaddam K, Ghavamzadeh A, Jahani M.

Fonte‎: Am J Hematol 2006;81(9):720.

Indicizzato‎: PubMed 16804937

DOI‎: 10.1002/ajh.20713

https://www.ncbi.nlm.nih.gov/pubmed/16804937 (apre una nuova finestra)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (apre una nuova finestra)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Fonte‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

Indicizzato‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (apre una nuova finestra)

The off-label use of recombinant FVIIa in the treatment of a patient with T-cell non-Hodgkin lymphoma who developed intra-abdominal and intra-pleural hemorrhages followed by high-dose methotreaxate therapy. (apre una nuova finestra)

Erduran E, Bahadir A, Mutlu M.

Fonte‎: Eur J Clin Med Oncol 2011;3(5):1-4.

Indicizzato‎: EMBASE 2012295551

https://www.worldcat.org/title/european-journal-of-clinical-medical-oncology/oclc/645421559&referer=brief_results (apre una nuova finestra)

The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review. (apre una nuova finestra)

Franchini M, Veneri D, Lippi G.

Fonte‎: Bone Marrow Transplant 2007;39(12):729-35.

Indicizzato‎: PubMed 17417659

DOI‎: 10.1038/sj.bmt.1705670

https://www.ncbi.nlm.nih.gov/pubmed/17417659 (apre una nuova finestra)

Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. (apre una nuova finestra)

Gerotziafas GT, Zervas C, Gavrielidis G, Tokmaktsis A, Hatjiharissi E, Papaioannou M, Lazaridou A, Constantinou N, Samama MM, Christakis J.

Fonte‎: Am J Hematol 2002;69(3):219-22.

Indicizzato‎: PubMed 11891811

https://www.ncbi.nlm.nih.gov/pubmed/11891811 (apre una nuova finestra)

Use of recombinant activated factor VII in a Jehovah's Witness patient. (apre una nuova finestra)

Hsieh A, Cheong I.

Fonte‎: Am J Emerg Med 2007;25(9):1085.e1-2.

Indicizzato‎: PubMed 18022514

DOI‎: 10.1016/j.ajem.2007.03.007

https://www.ncbi.nlm.nih.gov/pubmed/18022514 (apre una nuova finestra)

Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. (apre una nuova finestra)

Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, Kutti J, Mellqvist UH, Johansson JE, Glazer S, Hedner U.

Fonte‎: Haemostasis 1996;26 Suppl 1:159-64.

Indicizzato‎: PubMed 8904193

https://www.ncbi.nlm.nih.gov/pubmed/8904193 (apre una nuova finestra)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (apre una nuova finestra)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Fonte‎: Med Oncol 2010;27(1):16-9.

Indicizzato‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (apre una nuova finestra)

Recombinant factor VIIa for bleeding in refractory thrombocytopenia. (apre una nuova finestra)

Vidarsson B, Önundarson PT.

Fonte‎: Thromb Haemost 2000;83(4):634-5.

Indicizzato‎: PubMed 10780334

https://www.ncbi.nlm.nih.gov/pubmed/10780334 (apre una nuova finestra)

Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia. (apre una nuova finestra)

Zver S, Andoljšek D, Černelč P.

Fonte‎: Eur J Haematol 2004;72(6):455-6.

Indicizzato‎: PubMed 15128428

DOI‎: 10.1111/j.1600-0609.2004.00237.x

https://www.ncbi.nlm.nih.gov/pubmed/15128428 (apre una nuova finestra)

Management of bleeding complications of hematologic malignancies. (apre una nuova finestra)

Green D.

Fonte‎: Semin Thromb Hemost 2007;33(4):427-34.

Indicizzato‎: PubMed 17525900

DOI‎: 10.1055/s-2007-976178

https://www.ncbi.nlm.nih.gov/pubmed/17525900 (apre una nuova finestra)

Vitamin K deficiency in cancer patients referred to a hospital palliative care team with bleeding and the impact of vitamin K replacement on laboratory indicators of vitamin K status. (apre una nuova finestra)

Harrington DJ, Booth L, Dando N, Cottingham L, Beynon T.

Fonte‎: Int J Lab Hematol 2013;35(4):457-9.

Indicizzato‎: PubMed 23216984

DOI‎: 10.1111/ijlh.12035

https://www.ncbi.nlm.nih.gov/pubmed/23216984 (apre una nuova finestra)

Management of bleeding in patients with advanced cancer. (apre una nuova finestra)

Pereira J, Phan T.

Fonte‎: Oncologist 2004;9(5):561-70.

Indicizzato‎: PubMed 15477642

DOI‎: 10.1634/theoncologist.9-5-561

https://www.ncbi.nlm.nih.gov/pubmed/15477642 (apre una nuova finestra)

Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies. (apre una nuova finestra)

Castaman G, Bona ED, Schiavotto C, Trentin L, D'Emilio A, Rodeghiero F.

Fonte‎: Haematologica 1997;82(5):584-7.

Indicizzato‎: PubMed 9407726

https://www.ncbi.nlm.nih.gov/pubmed/9407726 (apre una nuova finestra)

Desmopressin and other synthetic vasopressin analogues in cancer treatment. (apre una nuova finestra)

Gomez DE, Ripoll GV, Girón S, Alonso DF.

Fonte‎: Bull Cancer 2006;93(2):E7-12.

Indicizzato‎: PubMed 16517412

https://www.ncbi.nlm.nih.gov/pubmed/16517412 (apre una nuova finestra)